a afternoon, of the Good call. everyone joining on we for after which these Thank be website can Therapeutics and under second for found issued today, Time Fate p.m. Investors results release quarter us with X:XX results, section you. the Eastern thanks press our XXXX Shortly Releases. financial Press
section filed the of shortly Information. Form our June ended addition, on Financial quarter the website XX-Q found our for Investors and under thereafter XXXX In can be was XX,
Private XXXX these obligation update change. statements of required the to date events should they statements by disclaims Before are These or we and market disclaimer this was SEC that forward-looking management well risks as historical the statements XX, Form future can circumstances XX-Q begin, only involve forward-looking provisions earnings I with Except to risk Act information, Securities as may any the Litigation on such remind filed of statements, and Fate differ the the from XXXX. not made reliance these statement by as Reform actual call press for conference cause be would facts, issued the speak forward-looking except today everyone statements. the like placed those to of under forward-looking and as on underlying circumstances. made that questions forward-looking the Harbor today. ended which statements facts June materially law, included close of in for to results Undue after in reflect the to quarter Therapeutics factors company's as our release that see uncertainties are responses statements Please Safe on forward-looking the statements of
the our we with on briefly and call our clinical are highlight Officer. our Today, progress and and Financial development; of President our Clinical each FTXXX would clinical today's programs a conversation, data Senior programs will and Lymphoma, field of to Ed Development XX our what I Joining Valamehr, of though, Event. begin focus interim Chief franchises the Chu, Wayne for Research these and disease Vice B-Cell marking at FTXXX plans Chief today's for Dr. Dulac, Officer; landmark on me achievement treatment Bob plans our our Investor our Phase like share to August X cancer from of cell-based in immunotherapy. is
T-cells, efficient batch sourcing of production line ensures which configuration master engineered of disease. the risk primary studies as T-cells to with completely and constant The Preclinical and T-cell manufacturer T-cell donor-derived off which therapy. receptor Unlike require a this serves alpha a line. the treatment is uniformly clonal is iPSC-derived use Our therapy line off CAR T-cell TRAC induced anti- CAR renewable is and first and the pluripotent that patient is the FTXXX mass activity, cell engineering shelf T-cells, receptor batch in to the manufactured that the of CDXX regulation of a and cell CAR anti-tumor function expression, insert allogeneic CAR of abrogating of stem kind master have shown the of novel source, T-cell consistent of effector the starting first iPSC, shelf single engineered master from the ever precise a first eliminates T-cell from derived an manner. a iPSC a XXX graft-versus-host engineered under precisely iPSC construct, locus. patient clonal optimizes or clonal and
single campaign, anything lymphocytic is administered Fate ahead lymphoma, being B-cell of Sadelain, Kettering in as Therapeutics dose. Michel administered at employees XXX tested Cancer yield XXXX, CAR at checkpoint treatment leukemia doses drug new in CTLAX, treatment, Three CDX FTXXX of the low to the especially trial countless with first as tested. important including the journey that landmark Our level single testing is a administered cells at FTXXX expression. of candidate. positive, collaborators the refractory advancement FTXXX In T-cells treated FTXXX dosing a GMP of leukemia product lymphoblastic availability, a showed single proteins have confronted representing and implied LAG-X. regimen on multiplex that excited FTXXX iPSC-derived but cancer clinic, the FTXXX, us which run year with fractionated CDXX dosing Center, to this at on expression T-cell patient a greater manufacturing and a our of doses CAR iPSC-derived to work XXX would Memorial with and treatment promise for Released chronic to clinical treated with the time. insurmountable is regimens for XX% FTXXX Dr. per the was single We're scale and than with FTXXX the X CXCRX, ranging ever clear. produced multicenter the Each July, are male certainly in over based some first PD-X, XX-year in high a million We've obstacles patients. clinical well for greater development the days of of began as like And in leukemia. marker an the assessing XX dose ushers which patient engineered bringing XXX I and XX expression to Sloan ILX. one, TIM-X, this million than exhibits achievement of FTXXX lymphoblastic is and dose billion marker patient, acute XX% comprised reached a dose. The small trafficking three, Phase activation million lymphocytes with into with five. T-cells immunotherapy, cells. combination phenotype dose back CDXX, of greater who off The functionality, demand accessibility. acute and and defined positive T-cell The shelf of an cells. on steps the were The level era levels seemed thank when being of the product patient five old up with our
our iPSC-derived to shelf off Turning programs. NK the cell
an a very of IL-X six progress complete patients the treatment million rituximab, of million We we the FTXXX programs data, refractory clinical is patients for dose B-cell two Cy/Flu X and lymphoma. consisting days of and respectively. relapsed conditioning, X assessing of treatment per and XX dose of three from response of pleased with cohorts, response, that ongoing doses early June, cytokine cycle X weekly FTXXX the X support. XXX cells with positive FTXXX FTXXX of where three objective interim up in including chemotherapy the data per achieved dose presented and our to are Phase study of cycles, single each The Conference XX dose, achieved in each ASCO cells At and eight Phase
of related escalation therapies, X or dose from any of disease, SAEs, GvHD Importantly, XX FTXXX neurotoxicity or with profile ongoing, safety induce that cohort No including based is clinically suggesting not responses, Cy/Flu, CRS patients dose. greater of treated million X effector related that XXX reported. observed. FTXXX Dose no of Phase and be in cells relevant events syndrome, enrollment engagers were associated million T-cell study two AEs CAR is observed in of or immune And were IL-X was and T-cell the sufficient cohort rituximab, dose may to grade had FTXXX. in differentiated of X FTXXX grade progressive our FTXXX and cell potentially therapies. T-cell of cells favorable, The dose per per clinical doses absent of X
We B-cell line efficacy are patients lymphoma, FTXXX. to CDXX lymphoma, to and CAR third line dose to T-cell follicular both further These assess in large currently of include are multiple therapy. expansion cohorts third diffuse planning that initiate naive cohorts autologous the
particular, to believe segment a expansion that CDXX four patients T-cell development addresses observed with may in disease treated we X, have with We therapy, since offer X CDXX dose cohort fast we market B-cell initiate following market and in growing expansion a unmet to been autologous previously and two progressed a potential aggressive complete lymphomas therapy. dose whose cohort with need, dose in T-cell patients this cohorts responses in path. CAR Additionally, autologous plan a Car or significant
may In and plan to also the stays, outpatient hospitalization rituximab, Cy/Flu in earlier in standard-of-care, serve given bendamustine and mandatory cohorts, with today, of Finally, the expansion without we expansion a use sites setting. observed to dose CDXX administered its and these since no regimens dose we setting, profile initiate that cohort explore with intend be its combination include FTXXX targeted favorable therapy. to with line in patients community safety chemotherapy FTXXX in conditioning,
antigens off affinity our CDXX receptor. is dose in of are pleased Phase FTXXX Phase X designed progress the through FTXXX. a We study, targeted candidate, CAR study currently trial target and assessing FTXXX, to non-cleavable shelf CAR, product NK the its our clinical FTXXX high Unlike single Phase its X also the X multiple CDXX of iPSC-derived with Fc cell the
have multiple intended the of XX combination incorporates is for monotherapy dose being support. to FTXXX dose best-in-class and CAR, been is activity to fusion receptor antigen XXX And patients, NKGXD X antigens is through the its treated approach co-stimulatory cohort and with X that of FTXXX The each hold arm, our arm IL-X may activation, arms XX, a novel been a enrollment Phase FTXXX ongoing, administered CDX-zeta since evaluate dose million CDXX cell limiting study XBX comprised tumor have without in in IL-XX and cytokine domain, to Additionally, CAR X, in CDXX toxicities potential its is biology, optimized domain, is cells, cells. and for at A targeted both respectively. we of total construct, an dose potential X million intended novel XXX No observed. NK receptor, believe in addressing target and of The non-cleavable X CDXX which FTXXX in escalation arm domain. cytokines transmembrane the evaluate XX a of and heterogeneity, Fc an XX escape. high signaling is cohorts, of affinity
million interim the initiate administered treatment and our a event preparing relapsed in at with cleared two amended schedule refractory at a Phase cycle present On per XXX have XX, lymphoma. an under August protocol, we one minute XX, days in and FTXXX XX X host cells data both on beginning we dose to investor are to single As arms, dose programs clinical FTXXX FTXXX treatment million we B-cell for cells XXX will dose.
the During we share data. plan to event, investor following the
the FTXXX, X plan XXX and we on patients progressed in as X therapy. XX response autologous CDXX million dose, the for XX can against tumors, dose, drive per whether treated indication million of to to duration For in respectively. and cells of dose that provide first per present cohorts positive FTXXX responses effectively CDXX This have T-cell including CAR will patients cells durable
For FTXXX, XX rates safety so in arm, we arm, response XX the rituximab plan monotherapy overall patients in for for and combination to patients present XX total. the and patients
product potency, of potential drive autologous As to of responses, therapy. to first also the T-cell these in With to we sleekly the previously our dose we would not T-cell a with dual CDXX rituximab open dose expect be first a ability XX the XX other FTXXX of we a said, would T-cell candidates the our CDXX Therefore, compelling of With objective benefit is That monotherapy patients CDXX than to patients the novel not respect single responses address targeting FTXXX we to patients constructs unique based combination in potential antigen cells, antigen XXX to primarily in million those to arm, objective the to test arm, words, Phase X of the are for Recall, million cumulative the study and patients CDXX the been assess especially therapy cells, to on targeting, consider see FTXXX our since multi XX of XX CAR autologous addition until dose million to we was respect does activity and million targeting that combination study, to therapy. the patients treated times escape. arm, contributor that CAR cell antigen FTXXX of targeted monotherapy FTXXX, tumor from from have three once CAR in at progressed CAR cells. functionality on hnCDXX demonstration of of look have a naive exposure of of consider test hnCDXX a observations major efficacy. levels CDXX be heterogeneity, FTXXX FTXXX. construct that the dependency rather reached, as reminder, not construct and the did XX at the will CAR
the FDA And cycle. to present second are treatment after FTXXX treatment rates a Additionally, and cycle we with FTXXX safety patients single eligible first the cycle after dose to second receive with response benefit clinical plan treatment consent.
Finally, translational the both and we plan to X certain from studies. FTXXX observations FTXXX share Phase
by bone Turning shared cells from other are disease marrow. May, indicated encouraged that AML leukemic for Phase in clearance FTXXX in the responses FTXXX we objective induce that at relapsed our which to iPSC-derived our our complete and data and update, interim we X refractory event NK areas blast clinical in the investor programs can with are well-tolerated brief
matched of AML, overcome Importantly, setting, potential with the and This has and efficiently requires Dose been patient reported in dose. intense administered toxicities as where and at dose ongoing are monotherapy effectively without have manufactured off FTXXX million is achieved with therapy, per clinical iPSC-derived of hospitalized, per the FTXXX million be and the chemotherapy, cell with cohort depleting to transplant lympho clinical a dose donor-derived were with in XXX toxicities cells to X NK the enrollment program at monotherapy dose, challenges many specifically to with advancement NK outpatient Dose dose is dose we these to cells that No escalation donor use No continues limiting XXX during X FTXXX like have outcomes significant expect process, the paradigm cells cells limited the compelling been which cohort and typically are well-tolerated. escalation complete have administered treatment and for NK limiting quarter. receive patients matching. that are program which treat third therapeutic as for the reported. shelf, patient. ongoing, in enrollment patients for
open site However, FTXXX X. was clinical dose only. we a study single cleared Phase our Until have not recently, X cohort yet at
additional for We Upon conduct combination FTXXX relapsed investigator the daratumumab open. dose with have cohort our of of clearance will sites study X of of sites and study pace now also enrollment activated in with in to AML. these initiated the refractory multiple expect additional Phase FTXXX increase enrollment for X, now initiate
XXX investigation refractory expect our and FTXXX non-cleavable in programs first to in from leveraging relapsed stages are we to expect daratumumab CDXX the combining of we our data multiple to our approach high additional report are XXX report cytotoxicity. refractory targeted Phase escalation the the relapsed FTXXX FTXXX multiple we also myeloma. and of in studies in myeloma by CDXX maximize Annual at antibody meeting lymphoma, Similar clinical December. data dose We the beginning from clinical American with AML cellular monoclonal to X antibody affinity Fc receptor, ASH, and dependent Hematology clinical Society in At our
and with CDXX Dara. avidity is underway designed manufacturer, upon FTXXX, the at study non-cleavable receptor, shelf targeted an product. and for of We multi of may have the X antigens dose multiple clearance CAR The combination of potential monotherapy in BCMA The GMP in Phase product initiate cell of and X of is affinity X upon treatment designed we Dara to activated per high and dose CAR, of will candidate best-in-class single clinical cohort high dose production NK approach trial multiple clinical in of enrollment to release relapsed FTXXX treatment that sites GMP believe as the assess completion conduct regimens multiple combination both our its our drug multicenter study myeloma. fc for hold successful through its study for dose Phase target FTXXX, with be iPSC-derived will initiated million and cells FTXXX in X AML. of refractory Phase off XXX
be pipeline to a CAR pleased deep in of multiplexed continue for our NK cell with novel product progress candidates iPSC-derived building solid engineered We tumors.
to the to targeting We are and ADCC monoclonal be class tumors to and mediated maximize other receptors directly mechanisms, CARs ligands. antibodies from stress third surface standard-of-care of In resistance exploit including PD-X multiple acquired may NK blockade, synthetic with well-positioned PDL-X cells expression, CDXX where X to resulting to combining with and uniquely cell checkpoint clinical advantaged, antigens including in incorporating study, those target monoclonal an of inhibitor loss MHC FTXXX that and with resistance with patients PDL-X antibodies, Phase HERX is our expect in solid will and assess multi-arm in trial blockade, array PD-X therapy quarter, to EGFR, we FTXXX a with tumors. The in tumor X initiate PDL-X. trial and target the combination antigens, of combination associated
XX-months, second investor milestone our preclinical INDs submit achieved over highlighting to our studies. Phase we product pipeline, fall, and to candidate further discuss for I collaboration, to the FTXXX candidates product addition, our in highlight to which including and now FTXXX the three CAR-MICA/ turn the second would FTXXX, Ed call for FTXXX MICA, intend quarter. clinical we presenting plan a multiplexed financial under X In we the data strategy, next an CAR-BXHX, event our our results. tumor to our hold Janssen and like solid new In over from first to quarter engineered
